Orion Valuation Multiples

Orion Overview

About Orion

Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. Orion mainly serves Finland but also has a presence in other European countries, North America and other countries.

Founded

2006

HQ

Employees

3.7K

Website

orion.fi

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2B

EBITDA: $835M

EV

$13B

Valuation Multiples

Multiples.vc

Start free trial

Orion Financials

Orion reported last 12-month revenue of $2B and EBITDA of $835M.

In the same LTM period, Orion generated $1B in gross profit, $835M in EBITDA, and $608M in net income.

Orion P&L

In the most recent fiscal year, Orion reported revenue of $2B and EBITDA of $819M.

Orion expects next 12-month revenue of XXX and NTM EBITDA of XXX

Orion Stock Performance

Orion has current market cap of $12B, and enterprise value of $13B.

Orion's stock price is $88.36.

Orion Valuation Multiples

Orion trades at 5.5x EV/Revenue multiple, and 15.1x EV/EBITDA.

Orion Financial Valuation Multiples

As of April 18, 2026, Orion has market cap of $12B and EV of $13B.

Equity research analysts estimate Orion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Orion has a P/E ratio of 20.5x.

Orion Margins & Growth Rates

Orion's revenue in the last 12 month grew by 10%.

Orion's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.

Orion's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Orion's rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Orion Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Orion M&A Activity

Orion acquired XXX companies to date.

Last acquisition by Orion was on XXXXXXXX, XXXXX. Orion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Orion Investment Activity

Orion invested in XXX companies to date.

Orion made its latest investment on XXXXXXXX, XXXXX. Orion invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).